SparX Group

Grand Cayman, Cayman Islands

SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.

$30.0M raised

Dec 2021

Series B

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has SparX Group raised?

SparX Group has raised $30.0M in total funding. The most recent round was Series B. The last funding was announced in December 2021.

Who are SparX Group's investors?

SparX Group's investors include Highlight Capital, Sangel Capital, Rotating Boulder Fund, Bosi Gongchuang.

Where is SparX Group headquartered?

SparX Group is headquartered in Grand Cayman, Cayman Islands.

What does SparX Group do?

SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.

What stage is SparX Group at?

SparX Group is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 31, 2021.

MLA

"SparX Group — Funding & Investors." VCBacked, December 31, 2021, https://www.vcbacked.co/company/sparx-group. Accessed July 2, 2026.

APA

VCBacked. (2021). SparX Group — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/sparx-group

Wikipedia (cite web)

{{cite web |title=SparX Group — Funding & Investors |url=https://www.vcbacked.co/company/sparx-group |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 31, 2021.